From: Decelerated DNA methylation age predicts poor prognosis of breast cancer
Stratified variables | DNAm age (quartile)a | Survival | Recurrence | ||
---|---|---|---|---|---|
N | HRb (95% CI) | N | HRb (95% CI) | ||
Menopause Status | |||||
Pre | First | 80 | 1.00 (ref) | 72 | 1.00 (ref) |
Second-Fourth | 149 | 0.87 (0.30–2.58) | 133 | 1.16 (0.42–3.21) | |
Post | First | 153 | 1.00 (ref) | 117 | 1.00 (ref) |
Second-Fourth | 583 | 0.40 (0.24–0.69) | 486 | 0.58 (0.29–1.16) | |
P for interaction | 0.3761 | 0.963 | |||
Clinical stage | |||||
Stage I&II | First | 136 | 1.00 (ref) | 103 | 1.00 (ref) |
Second-Fourth | 432 | 1.24 (0.62–2.49) | 341 | 0.80 (0.32–1.96) | |
Stage III&IV | First | 56 | 1.00 (ref) | 39 | 1.00 (ref) |
Second-Fourth | 131 | 0.39 (0.17–0.91) | 97 | 1.07 (0.39–2.92) | |
P for interaction | 0.159 | 0.665 | |||
ER status | |||||
negative | First | 99 | 1.00 (ref) | 77 | 1.00 (ref) |
Second-Fourth | 79 | 0.82 (0.31–2.15) | 61 | 0.60 (0.19–1.84) | |
positive | First | 95 | 1.00 (ref) | 67 | 1.00 (ref) |
Second-Fourth | 493 | 0.54 (0.29–0.99) | 385 | 0.77 (0.33–1.78) | |
P for interaction | 0.092 | 0.9972 | |||
HER2 status | |||||
negative | First | 156 | 1.00 (ref) | 119 | 1.00 (ref) |
Second-Fourth | 488 | 0.92 (0.51–1.64) | 382 | 1.14 (0.57–2.31) | |
Equivocal /positive | First | 37 | 1.00 (ref) | 25 | 1.00 (ref) |
Second-Fourth | 81 | 0.37 (0.09–1.58) | 63 | 0.18 (0.03–1.21) | |
P for interaction | 0.217 | 0.133 | |||
PAM50 | |||||
Luminal A | First | 25 | 1.00 (ref) | 13 | 1.00 (ref) |
Second-Fourth | 204 | 0.72 (0.17–2.97) | 149 | 0.59 (0.11–3.24) | |
Luminal B | First | 22 | 1.00 (ref) | 16 | 1.00 (ref) |
Second-Fourth | 100 | 0.65 (0.21–2.06) | 73 | 0.29 (0.06–1.46) | |
HER2-enriched&Basal-like | First | 84 | 1.00 (ref) | 61 | 1.00 (ref) |
Second-Fourth | 71 | 1.91 (0.67–5.41) | 48 | 0.66 (0.17–2.53) | |
P for interaction | 0.016 | 0.966 |